| Literature DB >> 27590234 |
Jinlong Chen1, Xu Yang2, Weiya Zhang1, Danhua Peng1, Yanan Xia1, Yi Lu1, Xiaodong Han3, Guangjie Song4, Jing Zhu1, Renping Liu5.
Abstract
This study was designed to examine whether resveratrol exerts the protective effects on LPS and cigarette smoke (LC)-induced COPD in a murine model. In lung histopathological studies, H&E, Masson's trichrome, and AB-PAS staining were performed. The cytokines (IL-6, IL-17, TGF-β, and TNF-α) and inflammatory cells in BALF were determined. The Beclin1 level in the lungs of mouse was analyzed. Compared with the LC-induced mouse, the level of inflammatory cytokines (IL-17, IL-6, TNF-α, and TGF-β) of the BALF in the resveratrol + cigarette smoke-treated mouse had obviously decreased. Histological examination of the lung tissue revealed that the resveratrol treatment attenuated the fibrotic response and mucus hypersecretion. In addition, resveratrol inhibited the expression of the Beclin1 protein in mouse lungs. The presented findings collectively suggest that resveratrol has a therapeutic effect on mouse LC-induced COPD, and its mechanism of action might be related to reducing the production of the Beclin1 protein.Entities:
Keywords: COPD; beclin1; mucus hypersecretion; resveratrol
Mesh:
Substances:
Year: 2016 PMID: 27590234 DOI: 10.1007/s10753-016-0430-3
Source DB: PubMed Journal: Inflammation ISSN: 0360-3997 Impact factor: 4.092